Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels

Antiviral Therapy

Volumn 11, Issue 4, 2006, Pages 491-498

  Andrade, Raúl J ^a   González, F Jesús ^a,b   Vázquez, Luis ^a   Cilvetti, Angel ^a   Camargo, Raquel ^a   García Cortés, Miren ^a   Martos VanDussen, Juan V ^a   Rosón, Pedro ^a   Lucena, M Isabel ^c   Clavijo, Encarnación ^c  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA MACULA CYSTOID EDEMA; RETINOPATHY; THROMBOCYTE COUNT; VASCULAR OPHTHALMOLOGICAL SIDE EFFECT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EYE DISEASES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETINAL DISEASES; RETINAL NEOVASCULARIZATION; RIBAVIRIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745801313     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124:1711-1719.
2. Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon-alpha. Br J Ophthalmol 1995; 79:150-152.
3. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85:1171-1173.
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-660.
5. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29.
6. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39:1185-1195.
7. Pugh CW, Ratcliffe P. Regulation of angiogenesis by hypoxia: role of HIF system. Nat Med 2003; 9:677-684.
8. Ferrara N, Davis Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
9. a (40 kd) (Pegasys®) and ribavirin (Copegus®) in naïve patients and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter, Teravic-4 study. Hepatology 2004;40(suppl 1):218A.
10. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6:3147-3152.
11. Gutterman JV. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91:1198-1205.
12. Biron CA. Interferons alpha and beta as immune regulators: a new look. Immunity 2001; 14:661-664.
13. Tilg H. New insights into the mechanisms of interferon-alpha: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017-1021.
14. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002; 36 (suppl 1):S3-S20.
15. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthal 1993; 111:350-356.
16. Yamada H, Mizobuchi K, Isogasi Y. Acute onset of ocular complications with interferon. Lancet 1994; 343:914.
17. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91:309-313.
18. Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27:1421-1427.
19. Lindner DJ. Interferon's as antiangiogenic agents. Curr Oncol Rep 2002; 4:510-514.
20. Ezekowitz RA, Mulliken JB, Folkman J Interferon alpha-2a therapy for life threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456-1463.
21. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993; 100:9-14.
22. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-583.
23. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000; 17:650-656.
24. Mazzanti R, Messerini L, Monsacchi L, et al. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997; 25:229-234.
25. Medina J, Caveda L, Sanz-Cameno P, et al. Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J Hepatol 2003; 38:660-667.
26. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35:1010-1021.
27. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998; 82:323-325.